Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
272 hedge funds and large institutions have $1.83B invested in Amicus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 120 increasing their positions, 82 reducing their positions, and 47 closing their positions.
54% more call options, than puts
Call options by funds: $2.4M | Put options by funds: $1.56M
46% more repeat investments, than reductions
Existing positions increased: 120 | Existing positions reduced: 82
1.99% more ownership
Funds ownership: 101.76% → 103.75% (+2%)
5% less funds holding
Funds holding: 286 → 272 (-14)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
28% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 47
28% less capital invested
Capital invested by funds: $2.55B → $1.83B (-$721M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$49.2M |
| 2 |
D.E. Shaw & Co
New York
|
+$26.3M |
| 3 |
Millennium Management
New York
|
+$26.2M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$19.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$90.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$53.9M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$31.8M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$22.4M |
| 5 |
JP Morgan Chase
New York
|
-$17.3M |
FOLD Hedge Fund Activity: Q2 2025 in Review
272 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2025, worth a combined $1.83B — down 28% from $2.55B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of FOLD and 34 opened new positions — a net loss of 13 holders — while 82 trimmed existing stakes and 120 added.
The largest buyer was Vestal Point Capital, adding an estimated $49.2M. The largest seller was Perceptive Advisors, cutting an estimated $90.7M.
- 272 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2025, down from 286 in Q1 2025.
- Funds reported $1.83B of Amicus Therapeutics stock for Q2 2025, down 28% quarter-over-quarter.
- 34 funds opened new Amicus Therapeutics positions in Q2 2025 and 47 closed out, a net change of -13 holders.
- The largest Amicus Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $49.2M added.
- The largest Amicus Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $90.7M sold.
Based on aggregated 13F filings for Q2 2025.